Abbott Laboratories (ABT) income statement
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3035% above fair value
$103.00−0.87 (-0.84%)
Close on Nov 20, 2026Market cap $178.23BP/E 33.1Yield 2.33%
Abbott Laboratories financial ratios
See a number that looks wrong?